0

Close
 
Upcoming Allied Market Research
2023
Intranasal Migraine Drugs Market

Intranasal migraine drugs Market

by Therapeutic Class (Corticosteroids, NSAID’s, Opioids, Antibiotics, Local Anesthesia, Antihistamines), by Indication (Common Migraine, Classic Migraine, Cluster Migraine, Others), by Range (Broad spectrum/ Chronic, Narrow spectrum/ Acute) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Third party manufacturing companies): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12660
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Intranasal Migraine Drugs Market

Request Now !

Intranasal drugs are an important part of migraine treatment. Migraine headache attacks are prevented by using these medicines. It assists in reducing headache pain and other symptoms like sensitivity to sound or light. Timely treatment enables a patient to get back to their normal routine shortly and may lessen your requirement for different pain medications. Migraine occurrences are not be prevented by this medication. New product launches by key manufacturers, rising R&D activities, and quick drug approvals by regulatory bodies such as the U.S. Food and Drug Administration for chronic and acute migraines have anticipated providing profitable opportunities in the coming years.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the intranasal migraine drugs market.

Top Impacting Factors

  • Increase in cases of acute migraine and chronic sinusitis, rise in demand for advanced treatments, and surge in healthcare expenditure are factors that drive the growth of the intranasal migraine drugs market.
  • In addition, collaborations, mergers & acquisitions between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of the novel developed drug in market; and technological advancements are some factors, which boost the market growth for intranasal migraine drugs.
  • However, less awareness for the alternative treatment for lung diseases, side effects linked with the drugs such as quick heartbeat, shortness of breath, and more may hinder the intranasal migraine drugs market growth. intranasal migraine drugs market
  • Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.

Intranasal migraine drugs Market Trends

New product launches to flourish the market

In January 2021, Impel Neuro Pharma received U.S. Food and Drug Administration (FDA) approval for the new drug application for INP104, for the acute treatment of migraine headaches.

In March 2021, Cipla received U.S FDA approval to treat migraine attacks for a nasal spray.

In June 2020, Tonix Pharmaceuticals acquired pain and non-addictive migraine treatment programs of Trigemina Inc. and will also acquire the license of TNX-1900 intranasal oxytocin. It has the potential to treat craniofacial pain and migraine.

In January 2019, Dr. Reddy's Laboratories received the US Food and Drug Administration (FDA) approval for a sumatriptan nasal splash to provide the intense therapy for headache.

Key Benefits of the Report

  • This study presents the analytical depiction of the intranasal migraine drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the intranasal migraine drugs market share.
  • The current market is quantitatively analyzed to highlight the intranasal migraine drugs market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the intranasal migraine drugs market.
  • The report provides a detailed intranasal migraine drugs market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the intranasal migraine drugs Report

  • Which are the leading players active in the intranasal migraine drugs market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the intranasal migraine drugs market?
  • What future projections would help in taking further strategic steps?
  • What is "Intranasal migraine drugs"?
  • What is "Intranasal migraine drugs” Market prediction in the future?
  • Who are the leading global players in the "Intranasal migraine drugs" Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Intranasal migraine drugs” Market report?

 Intranasal migraine drugs Market Report Highlights

Aspects Details
By Therapeutic Class
  • Corticosteroids
  • NSAID’s
  • Opioids
  • Antibiotics
  • Local Anesthesia
  • Antihistamines
By Indication
  • Common Migraine
  • Classic Migraine
  • Cluster Migraine
  • Others
By Range
  • Broad spectrum/ Chronic
  • Narrow spectrum/ Acute
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Third party manufacturing companies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Neuro Pharma, Roche, Sanofi, Novartis AG, Baxter International Inc., Merck, Lockhart ltd, Pfizer Inc., Dr. Reddy’s Laboratories, Aegis Therapeutics LLC
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: INTRANASAL MIGRAINE DRUGS MARKET, BY THERAPEUTIC CLASS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutic Class

    • 4.2. Corticosteroids

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. NSAID’s

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Opioids

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Antibiotics

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Local Anesthesia

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Antihistamines

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: INTRANASAL MIGRAINE DRUGS MARKET, BY INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Indication

    • 5.2. Common Migraine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Classic Migraine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cluster Migraine

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: INTRANASAL MIGRAINE DRUGS MARKET, BY RANGE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Range

    • 6.2. Broad Spectrum/ Chronic

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Narrow Spectrum/ Acute

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: INTRANASAL MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospital Pharmacies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacies

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Online Pharmacies

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Third Party Manufacturing Companies

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: INTRANASAL MIGRAINE DRUGS MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Therapeutic Class

      • 8.2.3. Market Size and Forecast, By Indication

      • 8.2.4. Market Size and Forecast, By Range

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Intranasal Migraine Drugs Market

        • 8.2.7.1. Market Size and Forecast, By Therapeutic Class
        • 8.2.7.2. Market Size and Forecast, By Indication
        • 8.2.7.3. Market Size and Forecast, By Range
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel

      • 8.2.8. Canada Intranasal Migraine Drugs Market

        • 8.2.8.1. Market Size and Forecast, By Therapeutic Class
        • 8.2.8.2. Market Size and Forecast, By Indication
        • 8.2.8.3. Market Size and Forecast, By Range
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel

      • 8.2.9. Mexico Intranasal Migraine Drugs Market

        • 8.2.9.1. Market Size and Forecast, By Therapeutic Class
        • 8.2.9.2. Market Size and Forecast, By Indication
        • 8.2.9.3. Market Size and Forecast, By Range
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Therapeutic Class

      • 8.3.3. Market Size and Forecast, By Indication

      • 8.3.4. Market Size and Forecast, By Range

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Intranasal Migraine Drugs Market

        • 8.3.7.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.7.2. Market Size and Forecast, By Indication
        • 8.3.7.3. Market Size and Forecast, By Range
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel

      • 8.3.8. Germany Intranasal Migraine Drugs Market

        • 8.3.8.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.8.2. Market Size and Forecast, By Indication
        • 8.3.8.3. Market Size and Forecast, By Range
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel

      • 8.3.9. Italy Intranasal Migraine Drugs Market

        • 8.3.9.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.9.2. Market Size and Forecast, By Indication
        • 8.3.9.3. Market Size and Forecast, By Range
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel

      • 8.3.10. Spain Intranasal Migraine Drugs Market

        • 8.3.10.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.10.2. Market Size and Forecast, By Indication
        • 8.3.10.3. Market Size and Forecast, By Range
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel

      • 8.3.11. UK Intranasal Migraine Drugs Market

        • 8.3.11.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.11.2. Market Size and Forecast, By Indication
        • 8.3.11.3. Market Size and Forecast, By Range
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel

      • 8.3.12. Russia Intranasal Migraine Drugs Market

        • 8.3.12.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.12.2. Market Size and Forecast, By Indication
        • 8.3.12.3. Market Size and Forecast, By Range
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel

      • 8.3.13. Rest Of Europe Intranasal Migraine Drugs Market

        • 8.3.13.1. Market Size and Forecast, By Therapeutic Class
        • 8.3.13.2. Market Size and Forecast, By Indication
        • 8.3.13.3. Market Size and Forecast, By Range
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Therapeutic Class

      • 8.4.3. Market Size and Forecast, By Indication

      • 8.4.4. Market Size and Forecast, By Range

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Intranasal Migraine Drugs Market

        • 8.4.7.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.7.2. Market Size and Forecast, By Indication
        • 8.4.7.3. Market Size and Forecast, By Range
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel

      • 8.4.8. Japan Intranasal Migraine Drugs Market

        • 8.4.8.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.8.2. Market Size and Forecast, By Indication
        • 8.4.8.3. Market Size and Forecast, By Range
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel

      • 8.4.9. India Intranasal Migraine Drugs Market

        • 8.4.9.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.9.2. Market Size and Forecast, By Indication
        • 8.4.9.3. Market Size and Forecast, By Range
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel

      • 8.4.10. South Korea Intranasal Migraine Drugs Market

        • 8.4.10.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.10.2. Market Size and Forecast, By Indication
        • 8.4.10.3. Market Size and Forecast, By Range
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel

      • 8.4.11. Australia Intranasal Migraine Drugs Market

        • 8.4.11.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.11.2. Market Size and Forecast, By Indication
        • 8.4.11.3. Market Size and Forecast, By Range
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel

      • 8.4.12. Thailand Intranasal Migraine Drugs Market

        • 8.4.12.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.12.2. Market Size and Forecast, By Indication
        • 8.4.12.3. Market Size and Forecast, By Range
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel

      • 8.4.13. Malaysia Intranasal Migraine Drugs Market

        • 8.4.13.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.13.2. Market Size and Forecast, By Indication
        • 8.4.13.3. Market Size and Forecast, By Range
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel

      • 8.4.14. Indonesia Intranasal Migraine Drugs Market

        • 8.4.14.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.14.2. Market Size and Forecast, By Indication
        • 8.4.14.3. Market Size and Forecast, By Range
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel

      • 8.4.15. Rest of Asia Pacific Intranasal Migraine Drugs Market

        • 8.4.15.1. Market Size and Forecast, By Therapeutic Class
        • 8.4.15.2. Market Size and Forecast, By Indication
        • 8.4.15.3. Market Size and Forecast, By Range
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Therapeutic Class

      • 8.5.3. Market Size and Forecast, By Indication

      • 8.5.4. Market Size and Forecast, By Range

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Intranasal Migraine Drugs Market

        • 8.5.7.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.7.2. Market Size and Forecast, By Indication
        • 8.5.7.3. Market Size and Forecast, By Range
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel

      • 8.5.8. South Africa Intranasal Migraine Drugs Market

        • 8.5.8.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.8.2. Market Size and Forecast, By Indication
        • 8.5.8.3. Market Size and Forecast, By Range
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel

      • 8.5.9. Saudi Arabia Intranasal Migraine Drugs Market

        • 8.5.9.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.9.2. Market Size and Forecast, By Indication
        • 8.5.9.3. Market Size and Forecast, By Range
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel

      • 8.5.10. UAE Intranasal Migraine Drugs Market

        • 8.5.10.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.10.2. Market Size and Forecast, By Indication
        • 8.5.10.3. Market Size and Forecast, By Range
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel

      • 8.5.11. Argentina Intranasal Migraine Drugs Market

        • 8.5.11.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.11.2. Market Size and Forecast, By Indication
        • 8.5.11.3. Market Size and Forecast, By Range
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel

      • 8.5.12. Rest of LAMEA Intranasal Migraine Drugs Market

        • 8.5.12.1. Market Size and Forecast, By Therapeutic Class
        • 8.5.12.2. Market Size and Forecast, By Indication
        • 8.5.12.3. Market Size and Forecast, By Range
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Aegis Therapeutics LLC

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Neuro Pharma

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Dr. Reddy’s Laboratories

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Novartis AG

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Pfizer Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Lockhart Ltd

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Roche

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Sanofi

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Merck

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Baxter International Inc.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR NSAID’S, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR OPIOIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR ANTIBIOTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR LOCAL ANESTHESIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR ANTIHISTAMINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR COMMON MIGRAINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR CLASSIC MIGRAINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR CLUSTER MIGRAINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR BROAD SPECTRUM/ CHRONIC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR NARROW SPECTRUM/ ACUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET FOR THIRD PARTY MANUFACTURING COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA INTRANASAL MIGRAINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. U.S. INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 28. U.S. INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. U.S. INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 30. U.S. INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. CANADA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 32. CANADA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 33. CANADA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 34. CANADA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE INTRANASAL MIGRAINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ITALY INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 53. ITALY INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 54. ITALY INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 55. ITALY INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. UK INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 61. UK INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 62. UK INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 63. UK INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 67. RUSSIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC INTRANASAL MIGRAINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. CHINA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 78. CHINA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 79. CHINA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 80. CHINA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 84. JAPAN INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. INDIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 86. INDIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 87. INDIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 88. INDIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 100. THAILAND INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 104. MALAYSIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 108. INDONESIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA INTRANASAL MIGRAINE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 121. BRAZIL INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 125. SOUTH AFRICA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 130. UAE INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 131. UAE INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 132. UAE INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 133. UAE INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 137. ARGENTINA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA INTRANASAL MIGRAINE DRUGS, BY THERAPEUTIC CLASS, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA INTRANASAL MIGRAINE DRUGS, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA INTRANASAL MIGRAINE DRUGS, BY RANGE, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA INTRANASAL MIGRAINE DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 142. AEGIS THERAPEUTICS LLC: KEY EXECUTIVES
  • TABLE 143. AEGIS THERAPEUTICS LLC: COMPANY SNAPSHOT
  • TABLE 144. AEGIS THERAPEUTICS LLC: OPERATING SEGMENTS
  • TABLE 145. AEGIS THERAPEUTICS LLC: PRODUCT PORTFOLIO
  • TABLE 146. AEGIS THERAPEUTICS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. NEURO PHARMA: KEY EXECUTIVES
  • TABLE 148. NEURO PHARMA: COMPANY SNAPSHOT
  • TABLE 149. NEURO PHARMA: OPERATING SEGMENTS
  • TABLE 150. NEURO PHARMA: PRODUCT PORTFOLIO
  • TABLE 151. NEURO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. DR. REDDY’S LABORATORIES: KEY EXECUTIVES
  • TABLE 153. DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
  • TABLE 154. DR. REDDY’S LABORATORIES: OPERATING SEGMENTS
  • TABLE 155. DR. REDDY’S LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 156. DR. REDDY’S LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 158. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 159. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 160. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 161. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. PFIZER INC.: KEY EXECUTIVES
  • TABLE 163. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 164. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 165. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 166. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. LOCKHART LTD: KEY EXECUTIVES
  • TABLE 168. LOCKHART LTD: COMPANY SNAPSHOT
  • TABLE 169. LOCKHART LTD: OPERATING SEGMENTS
  • TABLE 170. LOCKHART LTD: PRODUCT PORTFOLIO
  • TABLE 171. LOCKHART LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. ROCHE: KEY EXECUTIVES
  • TABLE 173. ROCHE: COMPANY SNAPSHOT
  • TABLE 174. ROCHE: OPERATING SEGMENTS
  • TABLE 175. ROCHE: PRODUCT PORTFOLIO
  • TABLE 176. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. SANOFI: KEY EXECUTIVES
  • TABLE 178. SANOFI: COMPANY SNAPSHOT
  • TABLE 179. SANOFI: OPERATING SEGMENTS
  • TABLE 180. SANOFI: PRODUCT PORTFOLIO
  • TABLE 181. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. MERCK: KEY EXECUTIVES
  • TABLE 183. MERCK: COMPANY SNAPSHOT
  • TABLE 184. MERCK: OPERATING SEGMENTS
  • TABLE 185. MERCK: PRODUCT PORTFOLIO
  • TABLE 186. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 188. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 189. BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
  • TABLE 190. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 191. BAXTER INTERNATIONAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL INTRANASAL MIGRAINE DRUGS MARKET
  • FIGURE 3. SEGMENTATION INTRANASAL MIGRAINE DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN INTRANASAL MIGRAINE DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINTRANASAL MIGRAINE DRUGS MARKET
  • FIGURE 11. INTRANASAL MIGRAINE DRUGS MARKET SEGMENTATION, BY BY THERAPEUTIC CLASS
  • FIGURE 12. INTRANASAL MIGRAINE DRUGS MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. INTRANASAL MIGRAINE DRUGS MARKET FOR NSAID’S, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. INTRANASAL MIGRAINE DRUGS MARKET FOR OPIOIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. INTRANASAL MIGRAINE DRUGS MARKET FOR ANTIBIOTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. INTRANASAL MIGRAINE DRUGS MARKET FOR LOCAL ANESTHESIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. INTRANASAL MIGRAINE DRUGS MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. INTRANASAL MIGRAINE DRUGS MARKET SEGMENTATION, BY BY INDICATION
  • FIGURE 19. INTRANASAL MIGRAINE DRUGS MARKET FOR COMMON MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. INTRANASAL MIGRAINE DRUGS MARKET FOR CLASSIC MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. INTRANASAL MIGRAINE DRUGS MARKET FOR CLUSTER MIGRAINE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. INTRANASAL MIGRAINE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. INTRANASAL MIGRAINE DRUGS MARKET SEGMENTATION, BY BY RANGE
  • FIGURE 24. INTRANASAL MIGRAINE DRUGS MARKET FOR BROAD SPECTRUM/ CHRONIC, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. INTRANASAL MIGRAINE DRUGS MARKET FOR NARROW SPECTRUM/ ACUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. INTRANASAL MIGRAINE DRUGS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 27. INTRANASAL MIGRAINE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. INTRANASAL MIGRAINE DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. INTRANASAL MIGRAINE DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. INTRANASAL MIGRAINE DRUGS MARKET FOR THIRD PARTY MANUFACTURING COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: INTRANASAL MIGRAINE DRUGS MARKET
  • FIGURE 37. Top player positioning, 2022
  • FIGURE 38. AEGIS THERAPEUTICS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. AEGIS THERAPEUTICS LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. AEGIS THERAPEUTICS LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. NEURO PHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. NEURO PHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. NEURO PHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. DR. REDDY’S LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. DR. REDDY’S LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. DR. REDDY’S LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. LOCKHART LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. LOCKHART LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. LOCKHART LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. ROCHE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ROCHE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. ROCHE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. MERCK: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. MERCK: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. MERCK: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 65. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 67. BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Intranasal Migraine Drugs Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers